Response to Comments: MolDX: Prostate Cancer Genomic Classifier Assay for Men with Localized Disease

This excerpt documents an administrative title revision for MolDX Decipher prostate cancer genomic classifier from 'favorable intermediate risk' to 'men with localized disease' and notes comment and effective dates. The provided text does not include specific coverage criteria, documentation requirements, limitations, or frequency limits; review the full LCD DL38339 for definitive coverage rules and clinical eligibility.

"Assay applies to men with localized prostate cancer (title revised from 'favorable intermediate risk' to 'localized disease')."

Sign up to see full coverage criteria, indications, and limitations.